Anticancer agent 89
Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2977251-05-9
- Formule: C32H29BrN2O10S3
- Masse moléculaire:777.68
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
Anticancer agent 89 (compound 6f) (0.01 mM; 24 h) has low cytotoxicity, shows high inhibition against three cell lines, SK-MEL-5, OVCAR-4, and A498[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines
-
Concentration:0-200 μg/mL
-
Incubation Time:24 hours
-
Result:Showed nontoxic under the doses of 90 μg/mL (FRHK-4), 90 μg/mL (Hep2), μg/mL (BGM), 90 μg/mL (Vero), and 100 μg/mL (Huh 7.5), respectively.
-
Cell Line:SK-MEL-5, OVCAR-4, and A498
-
Concentration:0.01 mM
-
Incubation Time:24 hours
-
Result:Inhibited SK-MEL-5, OVCAR-4, and A498 cell viability by 36.29%, 46.89%, and 36.08%, respectively.
Chemical Information
-
CAS No. 2977251-05-9
-
Masse moléculaire 777.68
-
Formule C32H29BrN2O10S3
-
SMILES
O=C(C1=C(N)C(C2=NC3=CC=CC=C3S2)=C(S[C@H]4[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@](OC(C)=O)([H])[C@@H](COC(C)=O)O4)S1)C5=CC=C(Br)C=C5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 89 Related Classifications
HY-151587 Related Classifications
Powered by Bioz